Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azacitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacitidine SCHEMBL17537438 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL706302 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL20143987 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL10024703 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL13390797 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL23815524 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL19996985 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Fazarabine SCHEMBL3278 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL1249475 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL7146234 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5070 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637498-B2 | PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-05-26 | — | — | US | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-12618064-B2 | Acetylated ribonucleic acids and uses thereof | HELIX NANOTECHNOLOGIES INC (US) | 2026-05-05 | — | — | US | claimed |
| EP-3787647-B1 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR TREATING OR PREVENTING DISC DEGENERATION | FIBROBIOLOGICS INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3976054-B1 | TIMED ADMINISTRATION OF DECITABINE AND 5-AZACYTIDINE FOR CANCER TREATMENT | CLEVELAND CLINIC FOUND (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4673226-A1 | RNA-BASED INHIBITORS OF TRNA MODIFYING ENZYMES | Yale University (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250346888-A1 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | HELIX NANOTECHNOLOGIES INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250345406-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | SHATTUCK LABS INC (US) | 2025-11-13 | — | — | US | claimed |
| EP-0567613-B1 | COMPOSITIONS FOR THERAPY AND PREVENTION OF CANCER | US GOV HEALTH & HUMAN SERV (US) | 2002-02-20 | — | — | EP | claimed |
| EP-1123111-A1 | MODULATION OF DNA METHYLTRANSFERASE EXPRESSION BY COMBINATION THERAPY | Methylgene, Inc. (CA) | 2001-08-16 | — | — | EP | claimed |
| EP-0668782-B1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | UNIV TEMPLE (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2001014566-A2 | ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOSIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-01 | — | — | WO | claimed |
| WO-2000023112-A9 | MODULATION OF GENE EXPRESSION BY COMBINATION THERAPY | METHYLGENE INC (CA) | 2000-08-31 | — | — | WO | claimed |
| WO-2000023112-A1 | MODULATION OF GENE EXPRESSION BY COMBINATION THERAPY | METHYLGENE, INC. (CA) | 2000-04-27 | — | — | WO | claimed |
| WO-1995028940-A1 | METHODS FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS | DEPARTMENT OF THE ARMY (US) | 1995-11-02 | — | — | WO | claimed |
| EP-0110955-B1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIV FLORIDA (US) | 1995-08-23 | — | — | EP | claimed |
| EP-0127677-B1 | READILY-ABSORPABLE FATTY ACID EMULSIONS | Advanced Drug Technology, Inc. (US) | 1990-08-01 | — | — | EP | claimed |
| EP-0286958-A2 | Process and means for the determination of nucleic acids | MERCK PATENT GmbH (DE) | 1988-10-19 | — | — | EP | claimed |